Home

Corona Remedies Ltd Quarterly Result

Image

Corona Remedies Ltd

NSE: CORONA

Net Profit - Last Quarter

₹ 52.32 Cr.

Last updated on: Jan 15, 2026

null Quarterly Results Key Highlights

  • The revenue of Corona Remedies Ltd for the Sep '25 is ₹ 363.57 crore as compare to the Jun '25 revenue of ₹ 348.56 crore.
  • This represent the growth of 4.31%a1# The ebitda of Corona Remedies Ltd for the Sep '25 is ₹ 80.91 crore as compare to the Jun '25 ebitda of ₹ 71.6 crore.
  • This represent the growth of 13%a1# The net profit of Corona Remedies Ltd for the Sep '25 is ₹ 52.32 crore as compare to the Jun '25 net profit of ₹ 46.2 crore.
  • This represent the growth of 13.25%a1#.

null Quarterly Results Analysis

Market Price of Corona Remedies Ltd

1M

1Y

3Y

5Y

Monitoring Corona Remedies Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
14 Jan 20261474.25
13 Jan 20261437.45
12 Jan 20261402.7
09 Jan 20261425.6
08 Jan 20261463.85
07 Jan 20261446.9
06 Jan 20261430.35
05 Jan 20261466.5
02 Jan 20261445.7
01 Jan 20261402.95

Historical Revenue of Corona Remedies Ltd

No data available

* All values are in crore

Historical EBITDA of Corona Remedies Ltd

No data available

* All values are in crore

Historical Net Profit of Corona Remedies Ltd

No data available

* All values are in crore

Corona Remedies Ltd News Hub

Shares of Corona Remedies list in B group

The equity shares of Corona Remedies (Scrip Code: 544644) are listed effective 15 December 2025 and

Read more

15 Dec 25

Corona Remedies Q2 PAT climbs 22% YoY to Rs 52 cr

Profit before tax (PBT) increased 21.67% year on year (YoY) to Rs 69.78 crore in Q2 FY26. Earnings B

Read more

03 Jan 26

Corona Remedies gains as Q2 PAT climbs 22% YoY to Rs 52 cr

Profit before tax (PBT) increased 21.67% year on year (YoY) to Rs 69.78 crore in Q2 FY26. Earnings B

Read more

05 Jan 26

Corona Remedies spurts on market debut

The stock was listed at Rs 1,452, exhibiting a premium of 36.72% to the issue price. So far, the sto

Read more

15 Dec 25

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for Quarterly Results of null

What key financial metrics are included in Corona Remedies Ltd's quarterly results?

Key financial metrics in Corona Remedies Ltd's quarterly results typically include revenue, net profit, earnings per share (EPS), and operating margins. Other metrics might include cash flow, operating expenses, and client metrics.

When does Corona Remedies Ltd announce its quarterly results?

Corona Remedies Ltd usually announces its quarterly results around mid-July for Q1, mid-October for Q2, mid-January for Q3, and mid-April for Q4, aligning with the end of each fiscal quarter. However, different finance companies have their respective schedules for announcing their quarterly results.

How does Corona Remedies Ltd's quarterly performance impact its stock price?

Corona Remedies Ltd's quarterly performance can lead to stock price volatility, with strong results often driving the price up, while disappointing results can cause it to drop. Investor sentiment and market expectations also play significant roles.

What is the impact of Corona Remedies Ltd's quarterly results on dividends?

The impact of Corona Remedies Ltd's quarterly results on dividends can influence dividend decisions, with strong performance potentially leading to increased or special dividends, while weaker results might result in stable or reduced dividends.

Are there any special announcements usually made during Corona Remedies Ltd's quarterly results?

Yes, Corona Remedies Ltd often makes special announcements during its quarterly results, including strategic updates, key client wins, and major contract renewals. They might also guide future performance and share insights on industry trends. These updates are typically highlighted in their press release. However, special announcements made during quarterly results may vary from company to company.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions